Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALFA 9801: Idarubicin vs Daunorubicin and IL-2 Maintenance in AML
NCT00931138Phase 3Completed
- Sponsor
- Acute Leukemia French Association
- Start
- Dec 1999
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of idarubicin and aldesleukin in acute myeloid leukemia (AML) (3 arms), sponsored by Acute Leukemia French Association. Primary endpoints: Event-Free Survival and Relapse Rate at 1 year. Started Dec 1999; status: completed.
02
Drugs
idarubicinaldesleukin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00931138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00931138.